Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Pre-Surgery training help older ovarian cancer patients recover better?

NCT ID NCT04284969

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called PROADAPT for women aged 70 and older with advanced ovarian cancer who need surgery. The program includes exercise, nutrition advice, education, and medication management before and after surgery. The goal is to see if it reduces serious complications and improves quality of life. About 292 participants will be randomly assigned to the program or standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PROADAPT program (behavioral intervention including exercise, nutrition, education, and medication management)
What this could lead to
If successful, this program could help elderly ovarian cancer patients recover faster and with fewer complications after surgery.
What could go wrong
This is a relatively early-stage study (Phase NA) with 292 participants, so results may not apply to all patients. The program is complex and may be hard to implement consistently across hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 292 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2021

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Woman ≥70 year old OR Woman ≥60 years with significant comorbid condition (modified Charlson index≥3) or disability (ADL score\<6/6); * Histologically or cytologically proven FIGO (International Federation of Gynecology and Obstetrics) stage III to IV epithelial ovarian cancer or peritoneal primary or fallopian tube. A cytological proof is accepted if associated with a ratio of CA125/CEA \>25 and a radiological pelvic mass. * Patient oriented towards a complex medical procedure defined by pelvic surgery preceded or not by antineoplastic treatment (neoadjuvant chemotherapy). * Therapeutic decision validated in a multidisciplinary consultation meeting * Life expectancy \> 3 months. * Written informed consent obtained. * Covered by a Health System where applicable. Exclusion Criteria: * Any other progressive malignant tumor interfering with the patient's prognosis. * Patient whose validated therapeutic management does not include cytoreductive surgery. * Patient unable to be regularly followed up for any reason (geographic, family, social, psychological). * Patient unable to understand the questionnaires. * Patient unable to follow and adhere to test procedures for geographic, social or psychological reasons. * Patient placed under guardianship or curatorship. * Patient deprived of liberty. * Concurrent participation in another interventional drug trial. * Patient already included in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer Surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Métropole Savoie

    RECRUITING

    Chambéry, 73000, France

  • CHU Nord Saint Etienne - Service oncologie médicale

    RECRUITING

    Saint-Priest-en-Jarez, 42270, France

  • CHU de St Etienne - Service gynécologie

    RECRUITING

    Saint-Priest-en-Jarez, 42270, France

  • Centre Georges François Leclerc

    RECRUITING

    Dijon, 21079, France

  • Centre hospitalier Annecy Genevois

    RECRUITING

    Pringy, 74374, France

  • Chu Bordeaux Pellegrin

    COMPLETED

    Bordeaux, 33000, France

  • Hôpital Croix Rousse

    RECRUITING

    Lyon, 69004, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • Médipôle Hôpital Mutualiste

    RECRUITING

    Villeurbanne, 69616, France

  • Service de Gériatrie, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet

    RECRUITING

    Pierre-Bénite, 69495, France

  • Villeurbanne Médipole MHP

    RECRUITING

    Villeurbanne, 69616, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.